Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials

September 07, 2023 By The ASCO Post Staff

Aaron C. Tan, PhD, MBBS, of the National Cancer Centre Singapore, discusses new findings on early evaluation of circulating tumor DNA via low-pass whole-genome sequencing. The results of his study suggest this method may represent an early pharmacodynamic biomarker of therapeutic response (particularly for targeted treatments) that may influence decisions on dose determination (Abstract 23).

Related Content